Drug Trial Radar · NCT01687608
Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With Hemophilia B
Last checked: Nov 19, 2026Latest source record: Mar 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Actual
Start
Feb 11, 2013
Primary completion
Jan 17, 2030
Study completion Jan 17, 2030
Sponsor
- Lead sponsor
- Baxalta now part of ShireTakeda (TAK)
- Sponsor type
- Industry
- First posted
- Sep 19, 2012
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety of single ascending IV doses of a Factor IX (FIX) Gene Therapy in up to 16 Adults with Hemophilia B.
Conditions
- Hemophilia B
Interventions
AskBio009Biological
Single dose IV injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of patients experiencing treatment-related adverse events by dose groupTime frame: Infusion to Week 3 and Infusion to end of study
- Change from baseline in clinical laboratory evaluationsTime frame: Change from baseline at week 3 and change from baseline at the end of study
Locations
15 sites in 1 country. Site status is shown where the registry gives one.
Orthopaedic Hemophilia Treatment Center
Los Angeles, California
Children's Hospital Los Angeles
Los Angeles, California
University of California Davis Medical Center
Sacramento, California
University of California at San Diego Medical Center
San Diego, California
U of Colorado School of Medicine, Hemophilia & Thrombosis Treatment Center
Aurora, Colorado
Emory University
Atlanta, Georgia
Rush University Medical Center
Chicago, Illinois
Children's Hospital of Boston
Boston, Massachusetts
University of Minnesota, Masonic Clinical Research Unit, Clinical and Translational Science Institute
Minneapolis, Minnesota
Mount Sinai Medical Center
New York, New York
The Hemophilia Center, Oregon Health and Science University
Portland, Oregon
Medical University of South Carolina
Charleston, South Carolina
Gulf States Hemophilia and Thrombosis Center
Houston, Texas
Bloodworks Northwest
Seattle, Washington
BloodCenter of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.